ASCO GU 2025

Combining ARPi with PARPi - discussing final OS of…

Milestones of ADT and ARPI treatment in the metastastic…

OS in the TALAPRO-2 trial

Darolutamide + ADT reduces risk of progression or death…

Testosterone Recovery after ADT and OS

Improved Survival with Enzalutamide + Lutetium

Darolutamide + ADT and Doetaxel improves survivas in…

Hypo-gonadism bad for survival?

Phase 2 Mevrometostat

MDT in OMPC

Who benefits most from ARPIs?

Mevrometostat - a new EZH2 inhibitor in mCRPC

Fish-oil supplement for pts on active surveillance

Final OS analyses

Final OS data for TALA + Enza

Testosterone Recovery

Radical Prostatectomy VS RT in HRPC

Radiation vs surgery in high risk prostate cancer

Mevrometostat + Enza: New option for mCRPC

Durvalumab in UTUC

ARPI for which patients?

ENZA-p showed OS benefit and improvement in QoL…

Enza+Lu ile artmis sagkalim

Yuksek risk PCa da RP vs RT

Oligometastatik PCa da MDT

UTUC de Neoadj. Durvalumab+Kemo

Hangi hastalarda ADT+ARPI

Triplet combination in RCC - there's no free lunch with…

KIM-1 - The most interesting biomarker for RCC?

Exciting new substances - but don't over-estimate phase…

AVION trial at mRCC

Casdatifan in refracting RCC

Prognostic and predictive biomarkers in mRCC: Looking…

Firstline Update Kidney Cancer

Proactive coaching of patients with TKI +/- IO therapy

KIM-1 in mRCC

KIM-1 in CheckMate 214

New data nccRCC

Advanced Renal Cell Cancer: Adding more drugs does not…

Cáncer de células renales avanzado: añadir más fármacos…

New data, but no new insights for adjuvant treatment of…

Exploratory analyses of pCR in NIAGARA: who benefits…

ADC + ICI - The future for MIBC?

Neoadjuvant chemo-immunotherapy in UTUC: new evidence…

Adjuvant Nivo - independent from previous therapy

A possible new standard for mUC

Sacituzumab Tirumotecan shows promising antitumor…

Updates neo/adjuvant therapy in MIBC

Neoadjuvant treatment for UTUC

ASCO GU 25 - Summary: Urothelial Cancer

Bladder-sparing approaches - are we there yet?

New drugs in mUC: The active field of ADCs

Nivo adjuvant in MIBC - a new standard

Durvalumab + Platinum-based chemotherapy shows…

The role of ctDNA in bladder cancer

Promising combination for perioperative setting

Phase 2 Mevrometastat

Preliminary results of neoadjuvant chemoimmunotherapy…

EV-Pembro continues to be the standard for mTCC

New FGFR3 inhibitor

Promising combination for perioperative setting

Nuevos fármacos en mUC: El campo activo de las ADCs

Testicular cancer: Reinventing the wheel

Metastatik seminomda Primer RPLND